Functionalized magnetic microspheres, preparation method and tyrosine phosphatase antibody assay kit
By coating the magnetic beads with functionalized MQ silicone resin, functionalized magnetic microspheres with multi-active sites are generated, which solves the problem of poor modification effect of magnetic microsphere functional groups in the prior art and improves tyrosine phosphoric acid The magnetic separation effect and detection sensitivity of enzyme antibodies simplify the preparation process and reduce costs.
Patent Information
- Application Number
- CN202410147811.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-02-02
AI Technical Summary
In the prior art, the surface functional group modification effect of magnetic microspheres is poor, resulting in low magnetic separation effect and detection accuracy of tyrosine phosphatase antibodies, and the biotin-streptavidin amplification system has been added. Preparation complexity and cost.
By simply functionalizing MQ silicone resin coating on ordinary magnetic beads or silica-coated magnetic beads, functionalized magnetic microspheres with multiple active sites are generated, and the affinity and specific binding ability of antigen antibodies are improved, and the magnetic properties are enhanced. Separation effect and detection sensitivity.
The magnetic separation effect and detection sensitivity of tyrosine phosphatase antibody assays have been significantly improved, the preparation process is simplified, and the cost is reduced, without the need for the use of a biotin-streptavidin amplification system.
Smart Images

Figure CN117969824B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of in vitro diagnosis, and specifically relates to a functionalized magnetic microsphere, a preparation method and a tyrosine phosphatase antibody assay kit. Background Art
[0002] Tyrosine phosphatase ICA512, also known as IA-2, is a member of the protein tyrosine phosphatase family and is located in the dense granules of pancreatic β cells. Tyrosine phosphatase autoantibodies (IA-2A) are antibodies against tyrosine phosphatases in pancreatic islet cells produced by the body's immune system. It, along with autoantibodies such as glutamic acid decarboxylase antibodies (GADA), insulin autoantibodies (IAA), tyrosine phosphatase antibodies (ZnT-8A) and islet cell antibodies (ICA), are all pancreatic autoantibodies and are markers of autoimmune damage to pancreatic β cells. They are key indicators for diagnosing autoimmune diabetes, including type 1 diabetes and latent autoimmune diabetes in adults (LADA), and are used to differentiate autoimmune diabetes from type 2 diabetes.
[0003] Common methods for clinical detection of tyrosine phosphatase antibodies include immunofluorescence, enzyme-linked immunosorbent assay and chemiluminescence. However, the operation of immunofluorescence is relatively complex, with high requirements for equipment and high cost. The enzyme-linked immunosorbent assay has low cost, but cumbersome operation, and poor accuracy and precision of the test results. Compared with the above technologies, magnetic particle chemiluminescence technology has the advantages of simple operation and accurate test results, so it has been widely used. CN 107044977 A discloses a tyrosine phosphatase antibody chemiluminescence immunoassay kit, which includes: purified tyrosine phosphatase-coated magnetic particle working solution, acridinium ester-labeled purified tyrosine phosphatase working solution, tyrosine phosphatase antibody calibration product, pre-excitation solution, and excitation solution. CN 113917142A discloses a kit for tyrosine phosphatase autoantibody magnetic particle chemiluminescence immunoassay, a preparation method and a detection method. It includes: magnetic particle-anti-biotin antibody solution, biotin-labeled tyrosine phosphatase antigen solution and enzyme-labeled anti-tyrosine phosphatase antibody solution. The magnetic particles used in the above-mentioned prior art are generally magnetic particles modified with surface functional groups, and the surface functional group modification effect is poor, and the binding force with tyrosine phosphatase antigen is poor, resulting in the magnetic separation effect and detection accuracy need to be further improved.
[0004] Patents CN 112877387 A and CN 113564213 A both disclose a method for preparing biomagnetic microspheres and their application in the separation and purification of target substances such as antibody substances. First, the magnetic microsphere body is chemically modified by using a silane coupling agent to obtain a magnetic microsphere A; then, acrylic acid molecules are covalently coupled to the outer surface of the magnetic microsphere A to introduce a carbon-carbon double bond to form a magnetic microsphere B containing a carbon-carbon double bond; acrylic acid monomer molecules (such as sodium acrylate) are polymerized by using a polymerization reaction of a carbon-carbon double bond to obtain an acrylic acid polymer chain having a linear main chain and a side chain containing a functional group, and the polymer is covalently coupled to the outer surface of the magnetic microsphere B through one end of the linear main chain to form an acrylic acid polymer modified magnetic microsphere C; biotin is covalently coupled through the functional group contained in the side chain of the polymer to obtain a biotin-modified biological magnetic microsphere D; through the specific binding action between biotin and avidin, an avidin-affinity protein covalently linked complex E is bound to the end of the polymer side chain, and an affinity complex is formed between biotin and avidin to obtain an affinity protein modified biological magnetic microsphere (affinity protein magnetic microsphere). Although the above method effectively improves the binding effect between magnetic microspheres and proteins, the controllability and uniformity of silane coupling agent modification are poor, and its own cross-linking reaction will lead to a decrease in surface modification effect and activity. In addition, the biotin and avidin reaction system increases the preparation process, and the polymerization coating process of acrylic polymers is relatively complicated and has poor controllability. At the same time, too many surface coating layers will also reduce the magnetic separation effect of magnetic microspheres to a certain extent. Summary of the invention
[0005] In view of the shortcomings and deficiencies of the above prior art, the primary purpose of the present invention is to provide a method for preparing functionalized magnetic microspheres. The functionalized magnetic microspheres of the present invention are simply coated with MQ silicone resin by one step of functionalization of ordinary magnetic beads or silica-coated magnetic beads, and have the advantages of good functional group modification effect and multiple active sites, which can significantly improve the affinity and specific binding ability with antigens and antibodies, and can significantly improve the magnetic separation effect and detection sensitivity without the need for a biotin-streptavidin amplification system.
[0006] Another object of the present invention is to provide a functionalized magnetic microsphere prepared by the above method.
[0007] Another object of the present invention is to provide a tyrosine phosphatase antibody assay kit comprising the functionalized magnetic microspheres.
[0008] The purpose of the present invention is achieved through the following technical solutions:
[0009] A method for preparing functionalized magnetic microspheres comprises the following preparation steps:
[0010] Silicate, active end-capping agent and magnetic beads are added to the solvent and stirred to mix evenly. The temperature is raised to 60-90° C. under the protection of an inert atmosphere. Then, an acid catalyst solution is added dropwise to carry out a stirring reaction. After the reaction is completed, the functionalized magnetic microspheres are obtained by filtering, washing and drying.
[0011] Furthermore, the silicate is at least one of sodium silicate, methyl orthosilicate and ethyl orthosilicate.
[0012] Furthermore, the active end-capping agent is at least one of 1,3-bis(aminopropyl)tetramethyldisiloxane, 1,3-bis(3-carboxypropyl)tetramethyldisiloxane, 1,3-bis(3-hydroxypropyl)tetramethyldisiloxane, 1,3-bis(mercaptopropyl)tetramethyldisiloxane, and 1,3-bis(3-glycidylpropyl)tetramethyldisiloxane.
[0013] Furthermore, the magnetic bead body in step (1) is selected from ferroferric oxide magnetic beads or silica-coated ferroferric oxide magnetic beads with an average particle size of 0.1 to 10 μm. More preferably, the ferroferric oxide magnetic beads are coated with silica. By using silica-coated ferroferric oxide magnetic beads, good binding sites can be increased during the generation of MQ silicone resin, further improving the coating effect.
[0014] Furthermore, in step (1), the mass ratio of the silicate, the active end-capping agent and the magnetic bead body added is 10:0.5-2:10-50.
[0015] Furthermore, the solvent in step (1) is selected to be a solvent that can dissolve or partially dissolve the reaction raw materials silicate and active end-capping agent, but does not dissolve the reaction product MQ silicone resin. Specifically, it can be selected as a mixed solvent of water and small molecule alcohol, such as a mixed solvent of water and ethanol, a mixed solvent of water and isopropanol, etc.; the volume ratio of the water and small molecule alcohol is 4-7:6-3.
[0016] Furthermore, the acid catalyst solution in step (1) is selected from hydrochloric acid solution or sulfuric acid solution; and the stirring reaction time is 1 to 4 hours.
[0017] The preparation principle of the functionalized magnetic microspheres is as follows: MQ silicone resin synthetic monomers and magnetic beads are dispersed in a specific solvent, and through the subsequent acid-catalyzed polymerization reaction of MQ silicone resin, the magnetic beads can provide binding sites for the core formation of MQ silicone resin, and the final generated MQ silicone resin is precipitated in situ on the surface of the magnetic beads, achieving good coating of the magnetic beads. The structural schematic diagram of the obtained functionalized magnetic microspheres is shown in Figure 1 The magnetic bead particles are tightly combined with the MQ silicone resin core, and a large number of active functional groups are evenly distributed on the outermost layer, which can significantly improve the affinity and specific binding ability with antigens and antibodies, thereby improving the magnetic separation effect and detection sensitivity.
[0018] A functionalized magnetic microsphere is prepared by the method.
[0019] A tyrosine phosphatase antibody assay kit comprises a tyrosine phosphatase antigen-coated functionalized magnetic microsphere solution, a goat anti-human IgG antibody fluorescent marker solution, a sample diluent, a calibration solution and a chemiluminescent substrate solution.
[0020] Furthermore, the goat anti-human IgG antibody fluorescent marker solution refers to a goat anti-human IgG antibody acridinium ester marker solution.
[0021] Furthermore, the concentration of the tyrosine phosphatase antigen-coated functionalized magnetic microsphere solution is 1-10 mg / mL; the concentration of the goat anti-human IgG antibody fluorescent marker solution is 0.1-1 mg / mL.
[0022] Furthermore, the sample diluent is a phosphate buffer solution containing 0.2% to 1% bovine serum albumin, 0.05% to 0.2% surfactant and 0.05% to 0.2% preservative.
[0023] Furthermore, the calibrator solution comprises tyrosine phosphatase antibody standard solutions with concentrations of 5.00 IU / mL, 50.00 IU / mL and 500.00 IU / mL, respectively.
[0024] Furthermore, the chemiluminescent substrate solution comprises a NaOH solution with a concentration of 0.05 to 0.25 mol / L and a H2O2 solution with a concentration of 0.05 to 0.2 mol / L.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] (1) The functionalized magnetic microspheres of the present invention are obtained by simply one-step functionalizing ordinary magnetic beads or silica-coated magnetic beads with MQ silicone resin, and have the advantages of good functional group modification effect and more active sites.
[0027] (2) The functionalized magnetic microspheres of the present invention can be used in a tyrosine phosphatase antibody assay kit to significantly improve the affinity and specific binding ability with antigen antibodies, and can significantly improve the magnetic separation effect and detection sensitivity without the need for a biotin-streptavidin amplification system. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Schematic diagram of the structure of the functionalized magnetic microspheres obtained in the present invention (A in the figure represents the active functional group). DETAILED DESCRIPTION
[0029] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto.
[0030] Example 1
[0031] A functionalized magnetic microsphere and tyrosine phosphatase antibody assay kit of this embodiment is prepared by the following method:
[0032] (1) 10 g of tetraethyl orthosilicate, 1.5 g of active end-capping agent 1,3-bis(3-carboxypropyl)tetramethyldisiloxane and 30 g of silicon dioxide-coated ferroferric oxide magnetic beads (average particle size of 0.5 μm) were added to a mixed solvent of 60 g of water and ethanol (V 水 :V 乙醇 =5:5) and stirred to mix evenly, heated to 80-85° C. under inert atmosphere protection, and then hydrochloric acid catalyst solution was added dropwise to stir and react for 2 h. After the reaction was completed, the mixture was filtered, washed, and dried in air flow to obtain carboxyl functionalized magnetic microspheres.
[0033] (2) The carboxyl functionalized magnetic microspheres obtained in step (1) and the tyrosine phosphatase antigen are mixed and incubated in a phosphate buffer solution at a mass ratio of 100:8, and diluted to a concentration of 5 mg / mL to obtain a tyrosine phosphatase antigen-coated functionalized magnetic microsphere solution.
[0034] (3) Acridinium ester (AE) and goat anti-human IgG antibody are mixed and incubated in a phosphate buffer solution and diluted to a concentration of 0.5 mg / mL to obtain a goat anti-human IgG-AE marker solution.
[0035] (4) 0.5% bovine serum albumin, 0.1% surfactant Triton X-100 and 0.1% preservative sodium azide were added to phosphate buffer to obtain a sample diluent.
[0036] (5) Using the sample diluent, the tyrosine phosphatase antibody standard was diluted to concentrations of 5 IU / mL, 50 IU / mL, and 500 IU / mL, respectively, to obtain a calibrator solution.
[0037] (6) The reagents were packaged according to the following formulas: 3.0 mL / bottle of functionalized magnetic microsphere solution coated with tyrosine phosphatase antigen, 6.0 mL / bottle of goat anti-human IgG-AE marker solution, 13 mL / bottle of sample diluent, 0.5 mL / tube of calibration solution (three tubes in total), and chemiluminescent substrate solution (0.1 mol / L NaOH solution, 1.0 mL / bottle; 0.1 mol / L H2O2 solution, 1.0 mL / bottle) to obtain a tyrosine phosphatase antibody assay kit.
[0038] The tyrosine phosphatase antibody assay kit obtained in this example was tested for detection performance:
[0039] 1. Magnetic separation efficiency test:
[0040] Different concentrations of calibration solutions were reacted with functionalized magnetic microsphere solutions coated with tyrosine phosphatase antigens for different times. After magnetic separation and collection of the reactants, the goat anti-human IgG-AE marker solution was added for reaction after washing. Pre-excitation solution and excitation solution were added to the reaction complex, and the relative luminescence intensity was determined by a fully automatic chemiluminescence immunoassay. The corresponding curve of reaction time and luminescence intensity was drawn, and the time when the luminescence intensity reached the highest and stable level was recorded as the reaction completion time. The shorter the reaction completion time, the higher the magnetic separation efficiency. The results showed that the reaction completion time of 5IU / mL, 50IU / mL and 500IU / mL calibration solutions was 4min, 6min and 7min, respectively, and the magnetic separation efficiency was high. Subsequent detection with a reaction time of 10min can ensure complete reaction.
[0041] 2. Linear range test
[0042] The reagent of this example was used to test 5 different concentrations of tyrosine phosphatase antibody company reference products within the linear range (5.00-500.00 IU / mL). Each company reference product was tested 3 times and the average value of each concentration was calculated. According to formulas (1), (2) and (3), the linear equation y=a+bx (y: test value of the reagent, x: actual value of the company reference product) and the correlation coefficient r were calculated.
[0043]
[0044]
[0045]
[0046] Where:
[0047] b-slope of the regression line; |a|-absolute value of the intercept of the regression line; r-correlation coefficient; X i - Actual value of the enterprise reference product; Y i -The mean of three repeated measurements of the company's reference product; i-1, 2, 3, ..., n; n-the number of samples measured.
[0048] The results showed that within the detection range of the kit, 5.00 to 500.00 IU / mL, the linear correlation coefficient r was 0.9979, and the linear relationship was good.
[0049] 3. Detection limit test
[0050] Five samples with a concentration close to 0.70 IU / mL were selected for testing. Each sample was tested 5 times, and the test results were sorted by size. The results showed that the test results were all <10.00 IU / mL, and there was no test result below the blank limit (0.50 IU / mL). This shows that the detection limit of the kit is not greater than 0.70 IU / mL.
[0051] 4. Repeatability Test
[0052] Under repeatability conditions, the tyrosine phosphatase antibody enterprise reference product with normal physiological value (4.50 IU / mL) and abnormal physiological value (52.60 IU / mL) was measured with the kit, and the measurement was repeated 10 times, and the average value of the measured value was calculated respectively ( X ) and standard deviation (S). The coefficient of variation (CV) was calculated according to formula (4).
[0053] CV=S / X *100% ................................................ (4);
[0054] The results of repeated measurements showed that the coefficient of variation (CV) of the normal physiological value reference was 2.05%, and the coefficient of variation (CV) of the abnormal physiological value reference was 1.82%, indicating good repeatability.
[0055] 5. Accuracy Test
[0056] The kit of this embodiment was used to measure three different concentrations of tyrosine phosphatase antibody corporate reference products within the linear range, namely high (200.00 IU / mL), medium (50.00 mg / L), and low (10.00 mg / L). Each corporate reference product was measured three times, the mean of the sample measurement results was calculated, and the relative deviation (Bias%) was calculated according to formula (5).
[0057] Bias%=( X -X) / X*100%........................ (5);
[0058] X - the mean of the sample measurement results; X-theoretical value of the measurement sample.
[0059] The results showed that the relative deviations of the high, medium and low concentrations of the enterprise reference products were -2.32%, 2.53% and 3.51% respectively. The accuracy of the enterprise reference product test was relatively high.
[0060] VI. Calibrator Measurement Accuracy Test
[0061] The kit calibrator was used as the sample for testing. After repeated measurement 3 times, the absolute deviation (M) of CAL1 (5 IU / mL) was calculated according to formula (6). D ), and the relative deviation (B) of CAL2 (50 IU / mL) and CAL3 (500 IU / mL) was calculated according to formula (7). i ).
[0062] M D =|Xi-T| ............................. (6);
[0063] Bi = (Xi-T) / T×100%................................ (7);
[0064] Where:
[0065] X i —Measured concentration value; T—labeled value of the matching calibration material.
[0066] The CAL1 calibrator was tested 3 times. D The results were 0.2IU / mL, 0.2IU / mL, and 0.1IU / mL respectively; the results of Bi measured by CAL2 calibrator three times were 0.87%, 1.85%, and 1.27% respectively; the results of Bi measured by CAL3 calibrator three times were -3.02%, -2.71%, and -2.76% respectively. The accuracy of calibrator testing was high.
[0067] 7. Sensitivity test
[0068] Repeat the blank sample measurement 20 times, calculate the mean and standard deviation (SD) of the 20 reactions, and calculate the corresponding concentration using the mean value + 2SD, which is the analytical sensitivity of the reagent.
[0069] The test results showed that the sensitivity of the kit in this example was 0.12 IU / mL.
[0070] Example 2
[0071] Compared with Example 1, in the preparation process of functionalized magnetic microspheres, ferroferric oxide magnetic beads were used instead of silicon dioxide-coated ferroferric oxide magnetic beads, and the rest of the process was the same.
[0072] The magnetic separation efficiency, linear correlation coefficient and sensitivity of the kit obtained in this example were tested. The results showed that the complete reaction time of 5 IU / mL, 50 IU / mL and 500 IU / mL calibration solution was 6 min, 7 min and 9 min, respectively; the linear correlation coefficient r was 0.9969; and the sensitivity result was 0.25 IU / mL.
[0073] By comparing the results of this example with those of Example 1, it can be seen that the magnetic separation effect and sensitivity of the detection kit obtained by using the functionalized magnetic microspheres prepared by using the silica-coated ferroferric oxide magnetic beads are improved to a certain extent compared with the detection kit prepared by using the ferroferric oxide magnetic beads. The reason is that the silica-coated ferroferric oxide magnetic beads have better binding properties with the MQ resin core, which can improve the coating modification effect of the functional group.
[0074] Example 3
[0075] The functionalized magnetic microspheres of this embodiment are compared with those of Embodiment 1, in which the active end-capping agents are 1,3-bis(aminopropyl)tetramethyldisiloxane (MM-NH), 1,3-bis(3-hydroxypropyl)tetramethyldisiloxane (MM-OH) and 1,3-bis(3-glycidylpropyl)tetramethyldisiloxane (MM-GOP), respectively, and the rest are the same.
[0076] The magnetic separation efficiency, linear correlation coefficient and sensitivity of the obtained kit were tested respectively, and the results are shown in Table 1 below.
[0077] Table 1
[0078]
[0079] It can be seen from the results in Table 1 that the kits prepared by using functionalized magnetic microspheres obtained with different active end-capping agents in the present invention all have good magnetic separation efficiency, linear detection range and sensitivity.
[0080] Comparative Example 1
[0081] Compared with Example 1, this comparative example uses silicon dioxide-coated ferroferric oxide magnetic beads surface-modified with silane coupling agent 3-[3-carboxyallylamide]propyltriethoxysilane to replace carboxyl functionalized magnetic microspheres. The preparation method of the surface-modified magnetic microspheres is as follows:
[0082] 1.5 g of silane coupling agent 3-[3-carboxyallylamide]propyl triethoxysilane and 30 g of silicon dioxide-coated ferroferric oxide magnetic beads (average particle size of 0.5 μm) were added to 60 g of a mixed solvent of water and ethanol (V 水 :V 乙醇=5:95) and stirred for 2 h. After the reaction was completed, the particles were filtered, washed, and dried in an air stream to obtain magnetic microspheres with surface carboxyl groups modified.
[0083] The magnetic separation efficiency, linear correlation coefficient and sensitivity of the kit obtained in this comparative example were tested. The results showed that the complete reaction time of 5 IU / mL, 50 IU / mL and 500 IU / mL calibration solution was 10 min, 13 min and 15 min respectively; the linear correlation coefficient r was 0.9923; and the sensitivity result was 0.56 IU / mL.
[0084] By comparing the results with those of Example 1, it can be seen that the present invention can significantly improve the magnetic separation efficiency and detection sensitivity by using functionalized MQ silicone resin to modify and coat the magnetic beads with functional groups, and has a better linear correlation compared to conventional surface coupling modification.
[0085] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for preparing functionalized magnetic microspheres coated with tyrosine phosphatase antigen, characterized in that: The method comprises the following preparation steps: The silicate, active end-capping agent and magnetic beads are added to the solvent and stirred to mix evenly, and the temperature is raised to 60-90°C under the protection of an inert atmosphere, and then the acid catalyst solution is added dropwise to react by stirring, and after the reaction is completed, the functionalized magnetic microspheres are filtered, washed and dried to obtain functionalized magnetic microspheres; the obtained functionalized magnetic microspheres are mixed and incubated with tyrosine phosphatase antigens in a phosphate buffer solution to obtain a functionalized magnetic microsphere solution coated with tyrosine phosphatase antigens; The silicate is at least one of methyl orthosilicate and ethyl orthosilicate; the active end-capping agent is at least one of 1,3-bis(aminopropyl)tetramethyldisiloxane, 1,3-bis(3-carboxypropyl)tetramethyldisiloxane, 1,3-bis(3-hydroxypropyl)tetramethyldisiloxane, 1,3-bis(mercaptopropyl)tetramethyldisiloxane, and 1,3-bis(3-glycidylpropyl)tetramethyldisiloxane; the magnetic bead body is selected from silicon dioxide-coated ferrosoferric oxide magnetic beads with an average particle size of 0.1 to 10 μm; and the acid catalyst solution is selected from hydrochloric acid solution or sulfuric acid solution.
2. The method for preparing a tyrosine phosphatase antigen-coated functionalized magnetic microsphere according to claim 1, characterized in that: The mass ratio of the silicate, active end-capping agent and magnetic bead body added is 10:0.5~2:10~50.
3. The method for preparing a tyrosine phosphatase antigen-coated functionalized magnetic microsphere according to claim 1, characterized in that: The solvent is selected as a mixed solvent of water and small molecule alcohol, and the volume ratio of the water and small molecule alcohol is 4-7:6-3.
4. A functionalized magnetic microsphere coated with a tyrosine phosphatase antigen, characterized in that: It is prepared by the method according to any one of claims 1 to 3.
5. A tyrosine phosphatase antibody assay kit, characterized in that: The method comprises the tyrosine phosphatase antigen-coated functionalized magnetic microsphere solution according to claim 4, a sheep anti-human IgG antibody fluorescent marker solution, a sample diluent, a calibration solution and a chemiluminescent substrate solution.
6. A tyrosine phosphatase antibody assay kit according to claim 5, characterized in that: The goat anti-human IgG antibody fluorescent marker solution refers to a goat anti-human IgG antibody acridinium ester marker solution.
7. A tyrosine phosphatase antibody assay kit according to claim 5, characterized in that: The concentration of the tyrosine phosphatase antigen-coated functionalized magnetic microsphere solution is 1-10 mg / mL; the concentration of the goat anti-human IgG antibody fluorescent marker solution is 0.1-1 mg / mL.
8. A tyrosine phosphatase antibody assay kit according to claim 5, characterized in that: The sample diluent is a phosphate buffer containing 0.2% to 1% bovine serum albumin, 0.05% to 0.2% surfactant and 0.05% to 0.2% preservative.
9. A tyrosine phosphatase antibody assay kit according to claim 5, characterized in that: The calibration solution comprises tyrosine phosphatase antibody standard solutions with concentrations of 5.00 IU / mL, 50.00 IU / mL and 500.00 IU / mL respectively; the chemiluminescent substrate solution comprises a NaOH solution with a concentration of 0.05-0.25 mol / L and a H2O2 solution with a concentration of 0.05-0.2 mol / L.
Citation Information
Patent Citations
A tyrosine phosphatase antibody chemiluminescence immunodetection kit and a preparing method thereof
CN107044977A
Biomagnetic microspheres as well as preparation method and application thereof
CN112877387A
Antibody type biological magnetic microsphere as well as preparation method and application thereof
CN113564213A
Kit for magnetic particle chemiluminescence immunodetection of tyrosine phosphatase autoantibody, preparation method and detection method
CN113917142A
Surface treatment agent for optical material, and optical material
CN104619796A
Cited By
Single-component acridinium ester luminescent substrate solution and preparation method thereof
CN120865895A
A single-component acridinium ester luminescent substrate solution and a preparation method thereof
CN120865895B
